A citation-based method for searching scientific literature

Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Marilyn K Glassberg, David Kardatzke, Talmadge E King, Lisa Lancaster, Steven A Sahn, Javier Szwarcberg, Dominique Valeyre, Roland M du Bois. Lancet 2011
Times Cited: 1091







List of co-cited articles
718 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, Peter M Hopkins, David Kardatzke, Lisa Lancaster,[...]. N Engl J Med 2014
71

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Luca Richeldi, Roland M du Bois, Ganesh Raghu, Arata Azuma, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Kevin R Flaherty, David M Hansell, Yoshikazu Inoue,[...]. N Engl J Med 2014
69

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
Ganesh Raghu, Harold R Collard, Jim J Egan, Fernando J Martinez, Juergen Behr, Kevin K Brown, Thomas V Colby, Jean-François Cordier, Kevin R Flaherty, Joseph A Lasky,[...]. Am J Respir Crit Care Med 2011
44

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu, Martine Remy-Jardin, Jeffrey L Myers, Luca Richeldi, Christopher J Ryerson, David J Lederer, Juergen Behr, Vincent Cottin, Sonye K Danoff, Ferran Morell,[...]. Am J Respir Crit Care Med 2018
996
31

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Kevin R Flaherty, Athol U Wells, Vincent Cottin, Anand Devaraj, Simon L F Walsh, Yoshikazu Inoue, Luca Richeldi, Martin Kolb, Kay Tetzlaff, Susanne Stowasser,[...]. N Engl J Med 2019
329
28

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, David M Hansell, Andrew G Nicholson, Kevin K Brown, Kevin R Flaherty, Paul W Noble, Ganesh Raghu,[...]. N Engl J Med 2011
615
25

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
Ganesh Raghu, Bram Rochwerg, Yuan Zhang, Carlos A Cuello Garcia, Arata Azuma, Juergen Behr, Jan L Brozek, Harold R Collard, William Cunningham, Sakae Homma,[...]. Am J Respir Crit Care Med 2015
912
21

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Ganesh Raghu, Kevin J Anstrom, Talmadge E King, Joseph A Lasky, Fernando J Martinez. N Engl J Med 2012
824
20

An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
William D Travis, Ulrich Costabel, David M Hansell, Talmadge E King, David A Lynch, Andrew G Nicholson, Christopher J Ryerson, Jay H Ryu, Moisés Selman, Athol U Wells,[...]. Am J Respir Crit Care Med 2013
20

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Oliver Distler, Kristin B Highland, Martina Gahlemann, Arata Azuma, Aryeh Fischer, Maureen D Mayes, Ganesh Raghu, Wiebke Sauter, Mannaig Girard, Margarida Alves,[...]. N Engl J Med 2019
333
19

Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
Brett Ley, Harold R Collard, Talmadge E King. Am J Respir Crit Care Med 2011
835
17

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Toby M Maher, Tamera J Corte, Aryeh Fischer, Michael Kreuter, David J Lederer, Maria Molina-Molina, Judit Axmann, Klaus-Uwe Kirchgaessler, Katerina Samara, Frank Gilberg,[...]. Lancet Respir Med 2020
117
17

Pirfenidone in idiopathic pulmonary fibrosis.
H Taniguchi, M Ebina, Y Kondoh, T Ogura, A Azuma, M Suga, Y Taguchi, H Takahashi, K Nakata, A Sato,[...]. Eur Respir J 2010
583
16

A multidimensional index and staging system for idiopathic pulmonary fibrosis.
Brett Ley, Christopher J Ryerson, Eric Vittinghoff, Jay H Ryu, Sara Tomassetti, Joyce S Lee, Venerino Poletti, Matteo Buccioli, Brett M Elicker, Kirk D Jones,[...]. Ann Intern Med 2012
565
16

Idiopathic pulmonary fibrosis.
Luca Richeldi, Harold R Collard, Mark G Jones. Lancet 2017
427
16

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Elizabeth A Fagan, Robert S Fishman, Ian Glaspole, Marilyn K Glassberg, Lisa Lancaster,[...]. Eur Respir J 2016
195
14

Idiopathic Pulmonary Fibrosis.
David J Lederer, Fernando J Martinez. N Engl J Med 2018
382
13

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Arata Azuma, Toshihiro Nukiwa, Eiyasu Tsuboi, Moritaka Suga, Shosaku Abe, Koichiro Nakata, Yoshio Taguchi, Sonoko Nagai, Harumi Itoh, Motoharu Ohi,[...]. Am J Respir Crit Care Med 2005
612
12

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Lutz Wollin, Eva Wex, Alexander Pautsch, Gisela Schnapp, Katrin E Hostettler, Susanne Stowasser, Martin Kolb. Eur Respir J 2015
320
12

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Carlo Vancheri, Michael Kreuter, Luca Richeldi, Christopher J Ryerson, Dominique Valeyre, Jan C Grutters, Sabrina Wiebe, Wibke Stansen, Manuel Quaresma, Susanne Stowasser,[...]. Am J Respir Crit Care Med 2018
92
11

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.
David A Lynch, Nicola Sverzellati, William D Travis, Kevin K Brown, Thomas V Colby, Jeffrey R Galvin, Jonathan G Goldin, David M Hansell, Yoshikazu Inoue, Takeshi Johkoh,[...]. Lancet Respir Med 2018
349
10

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
Luca Richeldi, Vincent Cottin, Roland M du Bois, Moisés Selman, Toshio Kimura, Zelie Bailes, Rozsa Schlenker-Herceg, Susanne Stowasser, Kevin K Brown. Respir Med 2016
203
10

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
Brett Ley, Jeffrey Swigris, Bann-Mo Day, John L Stauffer, Karina Raimundo, Willis Chou, Harold R Collard. Am J Respir Crit Care Med 2017
76
11

Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.
John Hutchinson, Andrew Fogarty, Richard Hubbard, Tricia McKeever. Eur Respir J 2015
314
9

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
Dinesh Khanna, Carlo Albera, Aryeh Fischer, Nader Khalidi, Ganesh Raghu, Lorinda Chung, Dan Chen, Elena Schiopu, Margit Tagliaferri, James R Seibold,[...]. J Rheumatol 2016
114
9

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Bruno Crestani, John T Huggins, Mitchell Kaye, Ulrich Costabel, Ian Glaspole, Takashi Ogura, Jin Woo Song, Wibke Stansen, Manuel Quaresma, Susanne Stowasser,[...]. Lancet Respir Med 2019
71
11

Idiopathic pulmonary fibrosis.
Fernando J Martinez, Harold R Collard, Annie Pardo, Ganesh Raghu, Luca Richeldi, Moises Selman, Jeffrey J Swigris, Hiroyuki Taniguchi, Athol U Wells. Nat Rev Dis Primers 2017
274
8

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
Steven D Nathan, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Ian Glaspole, Marilyn K Glassberg, David R Kardatzke, Monica Daigl, Klaus-Uwe Kirchgaessler, Lisa H Lancaster,[...]. Lancet Respir Med 2017
134
8

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Donald P Tashkin, Michael D Roth, Philip J Clements, Daniel E Furst, Dinesh Khanna, Eric C Kleerup, Jonathan Goldin, Edgar Arriola, Elizabeth R Volkmann, Suzanne Kafaja,[...]. Lancet Respir Med 2016
353
8

TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis.
Justin M Oldham, Shwu-Fan Ma, Fernando J Martinez, Kevin J Anstrom, Ganesh Raghu, David A Schwartz, Eleanor Valenzi, Leah Witt, Cathryn Lee, Rekha Vij,[...]. Am J Respir Crit Care Med 2015
151
7

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis.
Ulrich Costabel, Carlo Albera, Marilyn K Glassberg, Lisa H Lancaster, Wim A Wuyts, Ute Petzinger, Frank Gilberg, Klaus-Uwe Kirchgaessler, Paul W Noble. Respir Res 2019
22
31

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
Martin Kolb, Ganesh Raghu, Athol U Wells, Jürgen Behr, Luca Richeldi, Birgit Schinzel, Manuel Quaresma, Susanne Stowasser, Fernando J Martinez. N Engl J Med 2018
91
7

An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).
Ulrich Costabel, Carlo Albera, Lisa H Lancaster, Chin-Yu Lin, Philip Hormel, Henry N Hulter, Paul W Noble. Respiration 2017
64
10

Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Miya O Paterniti, Youwei Bi, Dinko Rekić, Yaning Wang, Banu A Karimi-Shah, Badrul A Chowdhury. Ann Am Thorac Soc 2017
62
11

Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.
Ulrich Costabel, Yoshikazu Inoue, Luca Richeldi, Harold R Collard, Inga Tschoepe, Susanne Stowasser, Arata Azuma. Am J Respir Crit Care Med 2016
150
7

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial.
Toby M Maher, Ellen M van der Aar, Olivier Van de Steen, Lisa Allamassey, Julie Desrivot, Sonia Dupont, Liesbeth Fagard, Paul Ford, Ann Fieuw, Wim Wuyts. Lancet Respir Med 2018
93
7

Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
Ganesh Raghu, Bernt van den Blink, Mark J Hamblin, A Whitney Brown, Jeffrey A Golden, Lawrence A Ho, Marlies S Wijsenbeek, Martina Vasakova, Alberto Pesci, Danielle E Antin-Ozerkis,[...]. JAMA 2018
75
9

Cyclophosphamide versus placebo in scleroderma lung disease.
Donald P Tashkin, Robert Elashoff, Philip J Clements, Jonathan Goldin, Michael D Roth, Daniel E Furst, Edgar Arriola, Richard Silver, Charlie Strange, Marcy Bolster,[...]. N Engl J Med 2006
890
7

Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study.
Richard J Allen, Joanne Porte, Rebecca Braybrooke, Carlos Flores, Tasha E Fingerlin, Justin M Oldham, Beatriz Guillen-Guio, Shwu-Fan Ma, Tsukasa Okamoto, Alison E John,[...]. Lancet Respir Med 2017
107
7

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Athol U Wells, Kevin R Flaherty, Kevin K Brown, Yoshikazu Inoue, Anand Devaraj, Luca Richeldi, Teng Moua, Bruno Crestani, Wim A Wuyts, Susanne Stowasser,[...]. Lancet Respir Med 2020
73
9

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study.
Vincent Cottin, Dirk Koschel, Andreas Günther, Carlo Albera, Arata Azuma, C Magnus Sköld, Sara Tomassetti, Philip Hormel, John L Stauffer, Indiana Strombom,[...]. ERJ Open Res 2018
36
19

Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.
Helen E Jo, Ian Glaspole, Christopher Grainge, Nicole Goh, Peter M A Hopkins, Yuben Moodley, Paul N Reynolds, Sally Chapman, E Haydn Walters, Christopher Zappala,[...]. Eur Respir J 2017
90
7

BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
Talmadge E King, Jürgen Behr, Kevin K Brown, Roland M du Bois, Lisa Lancaster, Joao A de Andrade, Gerd Stähler, Isabelle Leconte, Sébastien Roux, Ganesh Raghu. Am J Respir Crit Care Med 2008
366
6

High-dose acetylcysteine in idiopathic pulmonary fibrosis.
Maurits Demedts, Juergen Behr, Roland Buhl, Ulrich Costabel, Richard Dekhuijzen, Henk M Jansen, William MacNee, Michiel Thomeer, Benoit Wallaert, François Laurent,[...]. N Engl J Med 2005
639
6

Idiopathic pulmonary fibrosis.
Talmadge E King, Annie Pardo, Moisés Selman. Lancet 2011
6


Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis.
Anna L Peljto, Yingze Zhang, Tasha E Fingerlin, Shwu-Fan Ma, Joe G N Garcia, Thomas J Richards, Lori J Silveira, Kathleen O Lindell, Mark P Steele, James E Loyd,[...]. JAMA 2013
259
6

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
Martin Kolb, Luca Richeldi, Jürgen Behr, Toby M Maher, Wenbo Tang, Susanne Stowasser, Christoph Hallmann, Roland M du Bois. Thorax 2017
110
6

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
Harold R Collard, Christopher J Ryerson, Tamera J Corte, Gisli Jenkins, Yasuhiro Kondoh, David J Lederer, Joyce S Lee, Toby M Maher, Athol U Wells, Katerina M Antoniou,[...]. Am J Respir Crit Care Med 2016
489
6

Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts.
Enrico Conte, Elisa Gili, Evelina Fagone, Mary Fruciano, Maria Iemmolo, Carlo Vancheri. Eur J Pharm Sci 2014
159
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.